Does Aetna Cover Eliquis?

How Aetna Classifies Eliquis on Its Formulary

Aetna uses a tiered formulary system across its commercial, Medicare Advantage, and managed Medicaid product lines. Eliquis (apixaban) appears on most of these formularies, though its tier placement and cost-sharing structure vary by plan design and employer contract.

Commercial Plan Placement

On Aetna's standard commercial formularies, Eliquis typically sits at Tier 3 (preferred brand). This means the drug is covered but costs more than generic alternatives at Tier 1 or Tier 2. Some employer-sponsored plans negotiate custom formularies that may shift Eliquis to Tier 4 (non-preferred brand), which carries a higher copay or coinsurance percentage.

Medicare Advantage Placement

Aetna's Medicare Advantage Part D plans also cover Eliquis, but tier placement can differ from commercial products. The 2025 Medicare Part D redesign capped annual out-of-pocket drug spending at $2,000, a change that benefits patients on high-cost brand medications like Eliquis [1]. Under this cap, once a member reaches $2,000 in total out-of-pocket costs for the year, they pay nothing for the remainder of the benefit period.

Why Tier Placement Matters

The difference between Tier 3 and Tier 4 can translate to $30 to $60 more per month in copays. Checking your specific Aetna plan's formulary before filling a prescription is worth the five minutes it takes. Aetna publishes searchable formulary documents on its member portal, and your plan's Summary of Benefits and Coverage (SBC) lists the copay or coinsurance for each tier.

What Eliquis Costs With Aetna Insurance

The retail price of Eliquis without insurance runs approximately $550 to $620 for a 30-day supply of the standard 5 mg twice-daily dose [2]. Aetna coverage significantly reduces this figure, but the exact amount a member pays depends on plan type, tier, deductible status, and coverage phase.

Commercial Plan Cost Estimates

For Aetna commercial plans with Eliquis at Tier 3, members typically pay a fixed copay between $35 and $95 per month. Plans that use coinsurance instead of flat copays may charge 25% to 50% of the negotiated drug cost, which can result in higher out-of-pocket expenses, particularly before the deductible is met.

Medicare Advantage Cost Estimates

Aetna Medicare Advantage members may face different cost-sharing depending on where they fall in the Part D coverage phases. During the initial coverage phase, copays for Eliquis commonly range from $42 to $100. The Inflation Reduction Act's $2,000 annual out-of-pocket cap, fully implemented in 2025, means that no Aetna Medicare Advantage member pays more than $2,000 total for all covered Part D drugs in a calendar year [1].

Manufacturer Copay Assistance

Bristol-Myers Squibb and Pfizer offer an Eliquis co-pay card for commercially insured patients. Eligible members can pay as little as $10 per 30-day supply, with the program covering up to a specified annual maximum [3]. This card cannot be used by Medicare, Medicaid, or other federally funded program beneficiaries due to federal anti-kickback statute restrictions. The ARISTOTLE trial (N=18,201) established apixaban 5 mg twice daily as superior to warfarin for stroke prevention in atrial fibrillation, with a 21% reduction in stroke or systemic embolism (HR 0.79, 95% CI 0.66-0.95, P<0.001) and a 31% reduction in major bleeding [4].

Prior Authorization and Step Therapy Requirements

Not every Aetna plan covers Eliquis without conditions. Some plans impose utilization management controls that require additional steps before or during treatment.

When Prior Authorization Applies

Aetna may require prior authorization for Eliquis on certain Medicare Advantage and managed Medicaid plans. The prior authorization process typically requires your prescriber to submit clinical documentation confirming an FDA-approved indication, such as non-valvular atrial fibrillation (NVAF), deep vein thrombosis (DVT), or pulmonary embolism (PE) [5]. Processing takes 24 to 72 hours for standard requests and as few as 24 hours for urgent requests.

Step Therapy Protocols

Some Aetna plans require step therapy, meaning the plan will cover Eliquis only after the member has tried and failed (or has a documented contraindication to) a lower-cost anticoagulant. Warfarin is the most common step therapy requirement. The 2023 American College of Cardiology/American Heart Association (ACC/AHA) atrial fibrillation guideline states: "DOACs are recommended over warfarin in DOAC-eligible patients with AF" as a Class 1 recommendation [6]. This guideline language gives prescribers strong use when appealing step therapy requirements.

Quantity Limits

Aetna typically allows a 30-day supply per fill at retail pharmacies and a 90-day supply through mail-order pharmacy. The standard quantity limit aligns with the FDA-approved dosing of one tablet twice daily (60 tablets per 30-day supply for the 5 mg strength or the 2.5 mg reduced-dose strength) [5].

FDA-Approved Indications That Aetna Covers

Aetna's coverage of Eliquis applies to its FDA-approved indications. Using Eliquis for an off-label purpose may result in a coverage denial, though exceptions can sometimes be obtained with supporting evidence.

Stroke Prevention in Atrial Fibrillation

The primary indication driving Eliquis prescriptions is reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. The ACC/AHA estimates that atrial fibrillation affects approximately 6 million Americans, a number projected to reach 12 million by 2030 [6]. In the ARISTOTLE trial, apixaban demonstrated superiority over warfarin not only for efficacy but also for safety. The rate of major bleeding was 2.13% per year with apixaban versus 3.09% per year with warfarin (HR 0.69, P<0.001) [4].

DVT and PE Treatment

Eliquis is FDA-approved for the treatment of DVT and PE and for reduction in the risk of recurrent DVT and PE following initial therapy. The AMPLIFY trial (N=5,395) showed that apixaban was non-inferior to conventional therapy (enoxaparin followed by warfarin) for recurrent venous thromboembolism, while causing significantly less major bleeding (0.6% vs. 1.8%, P<0.001) [7].

Post-Surgical Prophylaxis

Eliquis carries FDA approval for prophylaxis of DVT following hip or knee replacement surgery. Coverage for this indication is typically straightforward, as it involves short-duration therapy (12 days for knee replacement, 35 days for hip replacement) with well-defined start and stop dates [5].

How to Check Your Specific Aetna Plan

Aetna administers hundreds of distinct plan designs. Two members with "Aetna" on their insurance cards may have very different formularies, copays, and utilization management requirements.

Online Formulary Lookup

Log in to the Aetna member portal at aetna.com or use the Aetna Health app. Manage to the pharmacy or prescription drug section and search for "apixaban" or "Eliquis." The tool will display your plan's tier placement, copay or coinsurance amount, and any prior authorization or step therapy requirements.

Contact Aetna Pharmacy Services

Call the number on the back of your Aetna ID card and ask to speak with the pharmacy benefits department. Request the following information: formulary tier for Eliquis, applicable copay or coinsurance, whether prior authorization or step therapy is required, and whether mail-order pricing offers any savings.

Ask Your Prescriber's Office

Many cardiology and primary care offices have staff dedicated to insurance verification. They can run a real-time pharmacy benefit check through their electronic health record system, which queries your Aetna plan and returns coverage details before the prescription is even written.

What to Do If Aetna Denies Eliquis Coverage

A coverage denial does not mean the decision is final. Aetna provides a structured appeals process, and clinical evidence strongly supports direct oral anticoagulants (DOACs) over warfarin for most patients.

Filing a Formulary Exception Request

If Eliquis is not on your plan's formulary or is placed at a non-preferred tier, your prescriber can submit a formulary exception request. This request should include the specific clinical rationale, such as contraindication to warfarin, poor INR control on warfarin, drug interactions with warfarin, or patient factors that make INR monitoring impractical. Dr. John Mandrola, a cardiac electrophysiologist, has noted: "The data supporting DOACs over warfarin is so strong that step therapy requirements for AF patients are increasingly hard to justify clinically" [8].

The Appeals Process

Aetna's internal appeals process involves two levels. The first-level appeal is reviewed by a clinical pharmacist or physician who was not involved in the original denial. If the first appeal is denied, a second-level appeal can be filed. For Medicare Advantage members, external review through an Independent Review Entity (IRE) is available after exhausting Aetna's internal process.

Peer-to-Peer Review

Your prescriber can request a peer-to-peer review, which is a direct conversation between your doctor and an Aetna medical director. This is often the most effective route for overturning a denial, because your prescriber can present the full clinical picture and respond to questions in real time.

Eliquis vs. Other Anticoagulants on Aetna Formularies

Aetna covers several anticoagulants, and understanding how Eliquis compares to alternatives on the formulary can help inform conversations with your prescriber.

Warfarin (Generic)

Warfarin sits at Tier 1 on virtually all Aetna formularies, with copays as low as $0 to $15. It remains effective but requires regular INR monitoring, has numerous food and drug interactions, and carries a higher bleeding risk than DOACs in head-to-head trials [4]. The ACC/AHA guideline designates DOACs as preferred over warfarin for eligible patients [6].

Xarelto (Rivarelbaan)

Rivaroxaban (Xarelto) typically occupies the same tier as Eliquis on Aetna formularies. The ROCKET AF trial (N=14,264) demonstrated rivaroxaban's non-inferiority to warfarin for stroke prevention in AF [9]. Unlike Eliquis, rivaroxaban is dosed once daily, which some patients prefer. Bleeding profiles differ between the two drugs, with a meta-analysis in the Journal of the American College of Cardiology showing that apixaban had lower rates of major bleeding and intracranial hemorrhage compared to rivaroxaban [10].

Savaysa (Edoxaban)

Edoxaban (Savaysa) may appear on Aetna formularies at similar or different tier placement. The ENGAGE AF-TIMI 48 trial (N=21,105) showed edoxaban's non-inferiority to warfarin, with lower rates of bleeding and cardiovascular death [11]. Edoxaban is less commonly prescribed than apixaban or rivaroxaban and may have different prior authorization requirements.

Special Populations and Dosing Considerations That Affect Coverage

Aetna's coverage criteria account for FDA-approved dosing modifications. Understanding these can prevent coverage issues at the pharmacy counter.

Reduced-Dose Criteria

The FDA-approved reduced dose of Eliquis is 2.5 mg twice daily. For stroke prevention in AF, this dose applies when a patient meets at least two of three criteria: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher [5]. Aetna covers both the 5 mg and 2.5 mg strengths, but a quantity limit edit may flag if the wrong strength is prescribed relative to patient characteristics.

Renal Impairment

Patients with end-stage renal disease (ESRD) on dialysis represent a population where Eliquis prescribing has expanded based on pharmacokinetic data and observational studies, despite limited randomized trial evidence in this group [12]. Aetna generally covers Eliquis for dialysis patients when prescribed at the appropriate dose, though prior authorization may be required for this indication on some plans.

Drug Interactions

Eliquis is metabolized by CYP3A4 and is a substrate of P-glycoprotein. Strong dual inhibitors of both pathways (such as ketoconazole or ritonavir) can increase apixaban exposure, and strong dual inducers (such as rifampin or phenytoin) can decrease it [5]. These interactions do not typically affect Aetna coverage but may influence your prescriber's choice of anticoagulant.

Saving Money on Eliquis With Aetna

Even with insurance coverage, the cost of a brand-name medication like Eliquis can add up over months and years of therapy.

Mail-Order Pharmacy

Aetna's mail-order pharmacy (typically CVS Caremark for plans using that pharmacy benefit manager) often provides a 90-day supply for the copay equivalent of two to two-and-a-half monthly fills. This represents a 17% to 33% savings compared to filling monthly at a retail pharmacy.

Preferred Pharmacy Networks

Some Aetna plans offer lower copays at preferred pharmacies. Check whether your plan has a preferred pharmacy network and whether your current pharmacy participates.

Patient Assistance Programs

For Aetna members who meet income eligibility criteria, Bristol-Myers Squibb offers a separate patient assistance program that provides Eliquis at no cost. This program is available to patients with household incomes at or below 300% of the federal poverty level who lack adequate prescription drug coverage [3].

The 2023 ACC/AHA guideline on atrial fibrillation management reinforces the importance of medication access, stating: "Clinicians should consider the patient's ability to afford and adhere to prescribed anticoagulation therapy when selecting an agent" [6]. This recommendation underscores that cost-related barriers to DOAC therapy are a recognized clinical concern, not just an administrative one.

Patients starting Eliquis for atrial fibrillation should have baseline renal function (serum creatinine and estimated GFR) and hepatic function checked, with renal function reassessed at least annually and more frequently in patients with CrCl 30-50 mL/min or with acute illness [5].